Prostate-specific antigen: Current status

Folia Biologica

Volumn 47, Issue 2, 2001, Pages 41-49

  Lukes, M ^a   Urban, M ^a   Zalesky M ^a   Zachoval, R ^a   Heracek J ^a   Zdarsky E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; ANTIGEN SPECIFICITY; BLOOD LEVEL; CANCER INCIDENCE; DENSITY; EARLY DIAGNOSIS; HUMAN; MALE; MOLECULAR BIOLOGY; NEOPLASM; PROSTATE CARCINOMA; PROSTATE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; TIME; VELOCITY;

EID: 0035068795     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Precipitating antigens of the normal human prostate
2. Tissue- and species-specific antigens of normal human prostatic tissue
3. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen
4. Age-specific reference for serum prostate-specific antigen
5. Prostate specific antigen and prostate gland volume: Correlation and clinical application
6. Determination of prostate volume with transrectal ultrasound: A study of intraobserver and interobserver variations
7. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma
8. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseases
9. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen
10. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis
11. Selection
12. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
13. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves
14. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
15. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial
16. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model
17. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels
18. Influence of digital examination, cystoscopy, transrectal ultrasonography and needle biopsy on the concentration of prostate-specific antigen
19. PSA, f/t-PSA, PSAD, PSA-TZ and PSA-velocity for prostate cancer prediction: A multivariate analysis
20. Total and transition zone prostate volume and age: How do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
21. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer
22. Cancer diagnosis with prostate specific antigen greater than 10 ng/ml and negative peripheral zone prostate biopsy
23. Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer
24. Some physicochemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma
25. Serum free prostate specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate
26. Serum prostatic specific antigen: In vitro stability and the effect of ultrasound rectal examination in vivo
27. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing
28. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate
29. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy
30. Serum prostate-specific antigen as prescreening test for prostate cancer
31. Prostate specific antigen expression by various tumors
32. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin
33. Importance of the ratio free prostate-specific antigen/total prostate-specific antigen for detection of prostate carcinoma
34. Evaluation of the influence of total prostate-specific antigen, age, and prostate volume on the ratio free/total prostate-specific antigen
35. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer
36. Age-specific reference ranges for serum prostate-specific in black men
37. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
38. Effect of cystoscopy, prostate biopsy and transuretheral resection of prostate on serum prostate-specific antigen concentration
39. Serum prostate-specific antigen in a community based population of healthy men: Establishment of age-specific reference ranges
40. Free, complexed and total serum prostate-specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios
41. Age-specific reference ranges for serum PSA
42. Reverse transcriptase-polymerase chain reaction assays for prostate cancer
43. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology
44. Analysis of percent free prostate-specific antigen for prostate cancer detection: Influence of total PSA, prostate volume and age
45. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
46. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
47. Prostate-specific antigen after anatomic radical retropubic prostatectomy
48. Natural history of progression after PSA elevation following radical prostatectomy
49. Molecular cloning and characterization of novel prostate antigen with cDNA's
50. Enhanced reverse transcriptase polymerase chain reaction for prostate-specific antigen combined with needle biopsy results: A superior predictor of pT3 disease
51. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma
52. The European randomized study of screening for prostate cancer (ERSPC): An update Members of the ERSPC, section Rotterdam
53. PSA density (PSAD). Role in patient evaluation and management
54. Half-life of prostate-specific antigen after radical prostatectomy: The decisive predictor of curative treatment?
55. Re: Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass
56. Longitudinal screening for prostate cancer with prostate-specific antigen
57. Comparison of percent free PSA and PSA density as method to enhance the specificity of PSA screening
58. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
59. Ejaculation increases the serum prostate-specific antigen concentration
60. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
61. Issues in the assessment of prostate-specific antigen immunoassays
62. Purification of a human prostate specific antigen
63. Determination of the "Reflex range" and appropriate cutpoints for percent free PSA in 413 men referred for prostatic evaluation using AxSYM system
64. Free and total PSA density in patients with prostate cancer and benign prostatic hyperplasia
65. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies
66. Ectopic production of prostate specific antigen by breast tumor metastatic to the ovary
67. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique
68. Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer prediction